Physician profile
Kara Bruning
NPI 1912385428
$3,612.56
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $244 · 2022: $550 · 2023: $953 · 2024: $1,867.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,819.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,819.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $890.43 | 2023-2024 | Freestyle Libre, Freestyle Libre 3 |
| Novo Nordisk INC | $595.78 | 2021-2024 | Ozempic, Wegovy, Rybelsus |
| Lilly USA, LLC | $503.65 | 2022-2024 | Mounjaro, Jardiance, Zepbound |
| Insulet Corporation | $244.52 | 2023-2024 | Omnipod |
| Amgen INC. | $176.26 | 2021-2024 | Tepezza, Repatha |
| Mannkind Corporation | $174.65 | 2023-2024 | Afrezza |
| Bayer Healthcare Pharmaceuticals INC. | $167.16 | 2022-2024 | |
| Eisai INC. | $158.51 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $103.00 | 2023-2024 | Jardiance |
| Dexcom, INC. | $81.16 | 2023-2024 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $62.69 | 2022-2024 | |
| Halozyme INC | $50.36 | 2023 | |
| Tandem Diabetes Care, INC. | $49.96 | 2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Radius Health, INC. | $39.36 | 2023-2024 | Tymlos |
| Antares Pharma, INC. | $36.12 | 2024 | Xyosted |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $35.68 | 2021 | |
| Abbvie INC. | $29.65 | 2022-2024 | |
| Novartis Pharmaceuticals Corporation | $28.34 | 2024 | |
| Astellas Pharma US INC | $24.16 | 2024 | Veozah |
| Ascensia Diabetes Care US INC. | $20.52 | 2024 | |
| Astrazeneca Pharmaceuticals Lp | $17.31 | 2022 | |
| Daiichi Sankyo INC. | $16.96 | 2021 | |
| Beta Bionics, INC. | $16.43 | 2023 | Ilet Bionic Pancreas |
| Amneal Pharmaceuticals LLC | $15.53 | 2023 | Unithroid |
| Esperion Therapeutics, INC. | $15.38 | 2021 | |
| Acella Pharmaceuticals, LLC | $15.16 | 2023 | NP Thyroid 60 |
| Medtronic, INC. | $14.82 | 2023 | Minimed 780g |
| Cequr Corporation | $14.76 | 2024 | Cequr Simplicity |
| Tolmar, INC. | $14.25 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kara Bruning listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.